Lilly Symbyax complete response
This article was originally published in Pharmaceutical Approvals Monthly
Lilly submits complete response during second quarter to an "approvable" letter for its olanzapine/fluoxetine combination Symbyax, the firm says July 24. Lilly "expects final FDA approval in 2004"; the NDA was submitted in fourth quarter 2002. The firm is highlighting the combo's rapid onset of action (1Pharmaceutical Approvals Monthly June 1, 2003, p. 5)...
You may also be interested in...
Lilly is highlighting a rapid onset of action and lack of treatment-emergent mania for its olanzapine/fluoxetine combination Symbyax, currently pending at FDA for the treatment of bipolar depression.
A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.
American Injectables gets a new CEO, while Hemostemix names a new chief medical officer.